Multicenter study of universal prophylaxis versus pre‐emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation
JB Lerman, CL Green, MR Molina… - Clinical …, 2023 - Wiley Online Library
Introduction Heart transplant (HT) recipients with prior exposure to cytomegalovirus (CMV
R+) are considered intermediate risk for CMV‐related complications. Consensus guidelines …
R+) are considered intermediate risk for CMV‐related complications. Consensus guidelines …
Multicenter study of universal prophylaxis versus pre-emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation
JB Lerman, CL Green, MR Molina… - Clinical …, 2023 - experts.umn.edu
Introduction: Heart transplant (HT) recipients with prior exposure to cytomegalovirus (CMV
R+) are considered intermediate risk for CMV-related complications. Consensus guidelines …
R+) are considered intermediate risk for CMV-related complications. Consensus guidelines …
Multicenter study of universal prophylaxis versus pre-emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation
JB Lerman, CL Green, MR Molina… - Clinical …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction Heart transplant (HT) recipients with prior exposure to cytomegalovirus (CMV
R+) are considered intermediate risk for CMV-related complications. Consensus guidelines …
R+) are considered intermediate risk for CMV-related complications. Consensus guidelines …
Multicenter study of universal prophylaxis versus pre-emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation.
JB Lerman, CL Green, MR Molina, V Maharaj… - Clinical …, 2023 - europepmc.org
Methods Retrospective analysis of all CMV R+ HT recipients from 6 US centers between
2010 and 2018 was performed. The primary outcome was the development of CMV …
2010 and 2018 was performed. The primary outcome was the development of CMV …